Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

567 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial.
Andersson C, Weeke P, Brendorp B, Køber L, Fosbøl EL, Sharma AM, Finer N, Caterson ID, Rode RA, James PT, Torp-Pedersen C. Andersson C, et al. Among authors: sharma am. Nutr Metab (Lond). 2009 Oct 14;6:42. doi: 10.1186/1743-7075-6-42. Nutr Metab (Lond). 2009. PMID: 19828038 Free PMC article.
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
Andersson C, Weeke P, Fosbøl EL, Brendorp B, Køber L, Coutinho W, Sharma AM, Van Gaal L, Finer N, James WP, Caterson ID, Rode RA, Torp-Pedersen C; SCOUT Executive Steering Committee; SCOUT investigators. Andersson C, et al. Among authors: sharma am. Metabolism. 2009 Aug;58(8):1109-15. doi: 10.1016/j.metabol.2009.04.003. Epub 2009 Jun 18. Metabolism. 2009. PMID: 19454355 Clinical Trial.
The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period.
Weeke P, Andersson C, Fosbøl EL, Brendorp B, Køber L, Sharma AM, Finer N, James PT, Caterson ID, Rode RA, Torp-Pedersen C. Weeke P, et al. Among authors: sharma am. BMC Endocr Disord. 2010 Feb 26;10:3. doi: 10.1186/1472-6823-10-3. BMC Endocr Disord. 2010. PMID: 20184783 Free PMC article.
Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP; SCOUT Investigators. Sharma AM, et al. Diabetes Obes Metab. 2009 Mar;11(3):239-50. doi: 10.1111/j.1463-1326.2008.00930.x. Epub 2008 Jul 29. Diabetes Obes Metab. 2009. PMID: 18671798 Clinical Trial.
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Legler UF, Shepherd GM, Rode RA, Perdok RJ, Renz CL, James WP; SCOUT Investigators. Caterson ID, et al. Among authors: sharma am. Diabetes Obes Metab. 2012 Jun;14(6):523-30. doi: 10.1111/j.1463-1326.2011.01554.x. Epub 2012 Jan 18. Diabetes Obes Metab. 2012. PMID: 22192338 Clinical Trial.
Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes.
Andersson C, van Gaal L, Caterson ID, Weeke P, James WP, Coutinho W, Finer N, Sharma AM, Maggioni AP, Torp-Pedersen C. Andersson C, et al. Among authors: sharma am. Diabetologia. 2012 Sep;55(9):2348-55. doi: 10.1007/s00125-012-2584-3. Epub 2012 May 26. Diabetologia. 2012. PMID: 22638548 Free article. Clinical Trial.
Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial.
Seimon RV, Espinoza D, Finer N, James WP, Legler UF, Coutinho W, Sharma AM, Van Gaal L, Maggioni AP, Sweeting A, Torp-Pedersen C, Gebski V, Caterson ID. Seimon RV, et al. Among authors: sharma am. Int J Obes (Lond). 2015 May;39(5):849-57. doi: 10.1038/ijo.2014.211. Epub 2014 Dec 18. Int J Obes (Lond). 2015. PMID: 25520249 Clinical Trial.
Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
Maggioni AP, Caterson I, Coutinho W, Finer N, Gaal LV, Sharma AM, Torp-Pedersen C, Bacher P, Shepherd G, Sun R, James P; SCOUT Investigators. Maggioni AP, et al. Among authors: sharma am. J Cardiovasc Pharmacol. 2008 Nov;52(5):393-402. doi: 10.1097/FJC.0b013e31818713d6. J Cardiovasc Pharmacol. 2008. PMID: 19033818 Clinical Trial.
567 results